subarachnoid hemorrhage
Conditions
Interventions
Propofol grou:Study administration stage I: Propofol 0.3-4 mg/kg/h for continuous sedation for 6 hours, and record relevant study information
Elution stage: Discontinue the administration of propofol for sedation and use cyclopofol at 0.06-0.8 mg/kg/h for sedation. Elution should last for at least 24 hours. Study administration stage II: Co
Cyclopofol group:Study administration stage I: Cyclopofol 0.06-0.8 mg/kg/h for continuous sedation for 6 hours, and record relevant study information
Elution stage: Discontinue the administration of cyclopofol for sedation and use propofol at a dose of 0.3 to 4 mg/kg/h for sedation. Elution should last for at least 24 hours. Study administration St
Sponsors
Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients who meet the diagnostic criteria for aneurysmal subarachnoid hemorrhage and have a Hunt-Hess grade of grade ? or above; 2. Receiving mechanical ventilation and requiring sedation treatment, with an estimated sedation time exceeding 48 hours; 3. Age: 18 to 60 years old; 4. The patient or their family members have a full understanding of the purpose and significance of this study, voluntarily participate in this clinical trial, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Have a history of allergy to propofol or cyclopofol components; 2. Patients with hemodynamic instability (whose systolic blood pressure remains below 90mmHg after treatment in accordance with the shock diagnosis/treatment norms of the Intensive Care Unit of Xiangya Hospital); 3. Severe liver and kidney function abnormalities (Child-Pugh grade C, CKD grade 5); 4. GCS score of 3 points, dilated and fixed pupils; 5. Combined with diseases that affect intracranial electrical activity, such as metabolic encephalopathy, inflammatory encephalopathy, Parkinson's syndrome, etc. 6. Patients with end-stage chronic diseases (such as malignant tumors); 7. Long-term use of medication for mental disorders or a history of alcohol abuse; 8. Pregnant and lactating patients; 9. Other circumstances where the researcher determines that one is not suitable to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative alpha variation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Electroencephalophysiological assessment;Evaluation of Cerebral Oxygen metabolism; | — |
Countries
China
Contacts
Public ContactLina Zhang
Xiangya Hospital, Central South University
Outcome results
None listed